Drug · DIN 02493896
NAT-LENALIDOMIDE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 1, 2021; first marketed September 1, 2021.
- Drug Identification Number (DIN)
- 02493896
- Company (DIN owner)
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lenalidomide L04AX04
- Class
- Human
- Record last updated
- July 20, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LENALIDOMIDE | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 1, 2021: NOC 26557Abbreviated New Drug Submission (ANDS)
Other DINs named NAT-LENALIDOMIDE
- DIN 02493837 · Marketed
- DIN 02493845 · Marketed
- DIN 02493861 · Marketed
- DIN 02493888 · Marketed
- DIN 02493918 · Marketed
- DIN 02493853 · Approved